Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2016 16:05 ET | Source: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update

SEATTLE, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today provided third quarter highlights and reported financial results...
October 10, 2016 07:10 ET | Source: Cascadian Therapeutics

Cascadian Therapeutics Announces Presentation of Tucatinib in Combination Therapy in Patients with Cutaneous HER2+ Metastatic Breast Cancer

SEATTLE, Oct. 10, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the presentation of clinical activity of tucatinib, its...
October 04, 2016 16:11 ET | Source: Cascadian Therapeutics

Cascadian Therapeutics Announces Proposal for Reverse Stock Split

SEATTLE, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that its board of directors has approved a plan for a...
September 28, 2016 08:00 ET | Source: Cascadian Therapeutics

Cascadian Therapeutics Announces Poster Presentations on Tucatinib at the European Society of Medical Oncology (ESMO) 2016 Congress

SEATTLE, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations on tucatinib...
September 20, 2016 08:00 ET | Source: Cascadian Therapeutics

Cascadian Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference

SEATTLE, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Julie Eastland, Chief Financial Officer, will...
September 06, 2016 08:00 ET | Source: Cascadian Therapeutics

Cascadian Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

SEATTLE, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Scott Myers, President and CEO, and Luke Walker,...
August 31, 2016 16:02 ET | Source: Cascadian Therapeutics

Cascadian Therapeutics Announces Approval of Nonproprietary Name “tucatinib” for Lead Product Candidate ONT-380

SEATTLE, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the United States Adopted Names (USAN) Council and...
August 08, 2016 16:02 ET | Source: Cascadian Therapeutics

Cascadian Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Reported positive interim results from Phase 1b “Triplet” study investigating ONT-380 in combination with trastuzumab and capecitabinePhase 2 “HER2CLIMB” study enrolling patientsSEATTLE, Aug. 08,...
June 29, 2016 08:00 ET | Source: Cascadian Therapeutics

Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer

SEATTLE, June 29, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic...
June 28, 2016 16:01 ET | Source: Cascadian Therapeutics

Cascadian Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of $46.0 million Concurrent Offerings of Common Stock and Series D Convertible Preferred Stock

SEATTLE, June 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today announced that it has closed the previously announced underwritten public offering of 40,250,000 shares...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right